AMPE Share Price

Open 0.54 Change Price %
High 0.60 1 Day -0.01 -1.79
Low 0.54 1 Week -0.01 -1.79
Close 0.55 1 Month -0.26 -32.10
Volume 302842 1 Year -3.55 -86.59
52 Week High 4.32
52 Week Low 0.52
AMPE Important Levels
Resistance 2 0.61
Resistance 1 0.58
Pivot 0.56
Support 1 0.52
Support 2 0.49
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
AKRX 33.09 1.13%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
WRES 0.09 28.57%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 100.00%
SPIR 0.02 100.00%
LOCM 0.09 50.00%
RITT 0.03 50.00%
CLNT 4.50 30.81%
CALI 3.45 29.21%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE)

AMPE Technical Analysis 5
As on 25th Apr 2017 AMPE Share Price closed @ 0.55 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.18 & Strong Sell for SHORT-TERM with Stoploss of 0.79 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMPE Target for April
1st Target up-side 0.89
2nd Target up-side 0.96
3rd Target up-side 1.02
1st Target down-side 0.71
2nd Target down-side 0.64
3rd Target down-side 0.58
AMPE Other Details
Segment EQ
Market Capital 132124608.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ampiopharma.com
AMPE Address
AMPE
5445 DTC Parkway
Suite 925
Greenwood Village, CO 80111
United States
Phone: 720-437-6500
Fax: 720-437-6501
AMPE Latest News
Technical Roundup On Two Stocks - Proteostasis Therapeutics (PTI), Ampio ...   Post Analyst   - 18th Apr 17
Ampio Pharmaceuticals, Inc. (NYSE:AMPE) Recent Ownership Changes   Post Analyst   - 17th Apr 17
Update - Ampio Pharmaceuticals Provides Corporate Update   Yahoo Finance   - 23rd Mar 17
Ampio Pharmaceuticals Provides Corporate Update   PR Newswire (press release)   - 20th Mar 17
Ampio Pharmaceuticals - Running On Fumes   Seeking Alpha   - 01st Feb 17
Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering   PR Newswire (press release)   - 29th Aug 16
Ampio Pharmaceuticals, Inc. Announces Updates On the Regulatory Path for FDA ...   PR Newswire (press release)   - 14th Oct 15
Ampio Pharmaceuticals (AMPE) Stock Tanks Today after Treatment Fails To Reach ...   TheStreet.com   - 20th Apr 15
News Ampio Pharmaceuticals Inc.AMPE   Wall Street Journal   - 20th May 11
0.61   MarketWatch   - 19th Apr 11
Interactive Technical Analysis Chart Ampio Pharmaceuticals, Inc. ( AMPE NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ampio Pharmaceuticals, Inc.
AMPE Business Profile
Ampio Pharmaceuticals, Inc. (Ampio), incorporated on March 29, 1996, is a development-stage biopharmaceutical company focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company is primarily focused on providing medicines to improve the health and quality of life of patients with minimal side effects. Ampio is engaged in developing pharmaceutical drugs and diagnostic products to identify, treat and prevent a range of human diseases, including metabolic disorders, eye disease, kidney disease, and acute and chronic inflammation diseases. In February 2013, it announced the incorporation and initiation of operations of Luoxis Diagnostics. In December 2013, Ampio Pharmaceuticals, Inc. announced that it had spun off its sexual dysfunction business into Vyrix Pharmaceuticals, Inc. Ampion is a non-steroidal anti-inflammatory biologic that has the potential to be used in a range of inflammatory conditions and autoimmune diseases. The active ingredient is aspartyl-alanyl diketopiperazine, referred to as DA-DKP, which is derived from two amino acids from human albumin and appears to have a significant role in the homeostasis of inflammation. Optina is a drug based on a low dose of the weak androgen, low-molecular-weight, very lipophilic steroid danazol. The Company’s in vitro data suggest that danazol has a biphasic effect on endothelial cells, which means at low doses, danazol decreases vascular leakage, while at higher concentrations an increase in vascular permeability is observed. This biphasic effect was supported by the efficacy of danazol in vivo at various BMIs.